Stay updated with breaking news from Thomasu Marron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
<p style="text-align:justify">Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of <em>non-small cell lung cancer (</em>NSCLC)<em>. </em> And in an early parallel study in humans, combining immunotherapy with dupilumab<em>—</em>an <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2018.00888/full" target="_blank">Interleukin-4</a> (IL-4) receptor-blocking ant...
/PRNewswire/ -- Riboscience, LLC, today announced the first presentation of data from the ongoing Phase 1 clinical trial of the ENPP1 inhibitor RBS2418 that...
The addition of an mRNA-based cancer vaccine to pembrolizumab extended RFS among patients with resected high-risk melanoma, according to study results presented at American Association for Cancer Research Annual Meeting.The benefit with the combination persisted regardless of patients’ tumor mutational burden status, findings of the randomized phase 2B KEYNOTE-942 trial showed.
Includes long-term follow-up data in patients with muscle-invasive bladder cancer and additional studies in colorectal, gastroesophageal and hepatocellular carcinoma ... | April 14, 2023